2017 – Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Efforts to improve outcomes beyond those achieved with 1 year of trastuzumab in patients with early-stage HER2-positive breast cancer are ongoing. Several different approaches, including extending the duration of trastuzumab to 2 years (HERceptin Adjuvant [HERA] trial),5 concurrent or sequential administration of lapatinib, a tyrosine kinase inhibitor, with trastuzumab (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation…

Devamını Oku